

Q1 2026 Financial Results

Total Revenues

\$3.5B

Adjusted EBITDA*

\$1.0B

Adjusted EPS*

\$0.59

Free Cash Flow*

Ex. Transaction and Restructuring Costs

\$459M

“ We delivered a strong first quarter, reflecting disciplined execution across our global businesses. Our performance reinforces the growth trajectory we outlined at our Investor Event in March. We saw continued momentum in key markets like Greater China and North America, progressed on launches and advanced our pipeline with multiple near-term catalysts. We expect to generate significant cash in 2026, providing flexibility to execute against our balanced capital allocation framework. Based on our strong start, we believe we are well positioned to deliver on our full-year guidance, and we remain focused on building a more durable, higher-quality growth profile for Viatriis.”



SCOTT A. SMITH
Chief Executive Officer

Delivering on Our 2026 Strategic Priorities

2026 Strategic Priorities

- ▶ Deliver strong financial performance
- ▶ Drive commercial execution, including launches
- ▶ Advance our pipeline, including regulatory decisions for six product candidates
- ▶ Execute disciplined and balanced capital allocation
- ▶ Target accretive in-market business development
- ▶ Evolve our organization and modernize for future growth

Execution

- Q1 performance ahead of our expectations, with 3% total revenue growth, 10% adjusted EBITDA growth, and 14% adjusted EPS growth operationally
- Strong commercial execution across our global portfolio, led by Greater China and North America
- Received approval and launched Effexor® for generalized anxiety disorder in Japan
- Cenerimod SLE Phase 3 trials fully enrolled; Selatogrel Phase 3 enrollment on track
- Returned \$140M of capital to shareholders through dividends paid
- On track to deliver identified cost savings, while reinvesting in the business to support future growth

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [First-Quarter 2026 Financial Results press release](#) on our website.

⁽¹⁾ Q1 2026 Free Cash Flow was \$348M. Excluding the impact of transaction-related and restructuring-related costs of \$111M, Q1 2026 Free Cash Flow was \$459M.

